Insider Selling: Merus (NASDAQ:MRUS) VP Sells 8,300 Shares of Stock

Merus N.V. (NASDAQ:MRUS) VP Harry Shuman sold 8,300 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $95.92, for a total transaction of $796,136.00. Following the sale, the vice president directly owned 11,002 shares in the company, valued at $1,055,311.84. This represents a 43.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Merus Stock Performance

Shares of NASDAQ MRUS traded down $0.02 during mid-day trading on Friday, hitting $96.08. 396,400 shares of the stock were exchanged, compared to its average volume of 1,274,618. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $96.28. The stock’s fifty day simple moving average is $91.85 and its two-hundred day simple moving average is $70.36. The company has a market cap of $7.29 billion, a P/E ratio of -18.13 and a beta of 1.26.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Quarry LP acquired a new stake in shares of Merus during the 3rd quarter worth approximately $42,000. Farther Finance Advisors LLC grew its holdings in Merus by 10,400.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 525 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 520 shares during the period. Longfellow Investment Management Co. LLC bought a new stake in shares of Merus during the 3rd quarter valued at $75,000. CWM LLC raised its position in shares of Merus by 299.0% during the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 601 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in Merus in the third quarter valued at about $114,000. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on MRUS shares. Citigroup downgraded Merus from a “buy” rating to a “neutral” rating and cut their price objective for the company from $101.00 to $97.00 in a research report on Monday, September 29th. William Blair cut Merus from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Alliance Global Partners initiated coverage on shares of Merus in a report on Monday, August 25th. They set a “buy” rating and a $90.00 price objective on the stock. Industrial Alliance Securities set a $90.00 price objective on shares of Merus in a research report on Monday, August 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Merus in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Merus currently has a consensus rating of “Hold” and an average target price of $93.56.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.